Abstract
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Controlled Clinical Trial
MeSH terms
-
Anorexia
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects*
-
Antibiotics, Antineoplastic / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Fatty Acids, Unsaturated / administration & dosage
-
Fatty Acids, Unsaturated / adverse effects
-
Fatty Acids, Unsaturated / therapeutic use
-
Female
-
Humans
-
Infusions, Intravenous
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
Substances
-
Antibiotics, Antineoplastic
-
Fatty Acids, Unsaturated
-
leptomycin B